Abstract 134P
Background
Although endoscopic surveillance remains the gold standard for diagnosing asymptomatic gastric cancer (GC) patients, associated costs and its invasive nature render it inadequate as a screening approach. Development of less invasive tests is needed for surveillance of early stage GCs. Over the last decade, tumor-derived miRNAs in peripheral blood are emerging as promising disease biomarkers. Herein we have conducted a comprehensive miRNA expression profiling, followed by bioinformatic analysis to establish a novel serum-based miRNA signature for the diagnosis of patients with GC.
Methods
We analyzed tissue miRNA expression profiles in three patient cohorts (n = 602) in an in-silico discovery step, during which the robustness of candidate biomarkers was tested and validated. The performance of this miRNA signature was evaluated in a serum training cohort (n = 327). Using a logistic regression model, the panel was further refined, and this circulating miRNA signature was validated in two prospective cohorts (n = 174, 175).
Results
Genome-wide analysis of miRNA expression data resulted in identification of 10-miRNAs that distinguished cancer tissues from normal mucosa in three independent datasets (AUC = 0.984, 0.939 and 1.000). Using a serum training cohort, the miRNA candidates were further refined to six-circulating-miRNA signature. This miRNA signature demonstrated a robust diagnostic value in the training cohort. Subsequently we demonstrated robustness of the signature in two prospective cohorts (AUC = 0.87, 0.86). Remarkably, the 6-circulating-miRNA signature was able to detect early stage GC patients robustly (AUC = 0.855). Furthermore, the signature was significantly superior at identifying patients with GC to conventional tumor markers, CEA (P = 0.0001) and CA19-9 (P = 0.0001).
Conclusions
Using a comprehensive data analysis followed by substantial clinical validations, involving over 1600 GC tissue and serum specimens across 7 independent cohorts, we developed a novel 6-circulating-miRNA signature, which demonstrated an unprecedented diagnostic value and a great promise for early non-invasive detection of GC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Daisuke Izumi.
Funding
NIH.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
285TiP - Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
Presenter: Christine Mauz-koerholz
Session: Poster display session
Resources:
Abstract
294P - Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with long-term follow-up
Presenter: Li-rong Wu
Session: Poster display session
Resources:
Abstract
295P - Development and validation of M1 substages for previously untreated metastatic nasopharyngeal carcinoma
Presenter: Sik Kwan Chan
Session: Poster display session
Resources:
Abstract
296P - Nasopharyngeal carcinoma: A retrospective review of outcome in a single institution
Presenter: Wan Ping Ch' ng
Session: Poster display session
Resources:
Abstract
297P - Global longitudinal assessment of treatment outcomes in nasopharyngeal carcinoma (GLANCE-NPC) study
Presenter: Myung-Ju Ahn
Session: Poster display session
Resources:
Abstract
298P - Long-term complication and outcomes after induction chemotherapy with TPF followed by chemoradiotherapy for nasopharyngeal cancer
Presenter: Sang-Hee Cho
Session: Poster display session
Resources:
Abstract
299P - Weekly versus triweekly concurrent chemoradiation for nasopharyngeal cancer
Presenter: Sudibio Sudibio
Session: Poster display session
Resources:
Abstract
300P - Endoscopic nasopharyngectomy for localized stage I nasopharyngeal carcinoma
Presenter: Ming-Yuan Chen
Session: Poster display session
Resources:
Abstract
301P - Oncological outcome following 3 Drug NACT for Bucco-Alveolar carcinoma with Supra-notch ITF extension
Presenter: Karan Gupta
Session: Poster display session
Resources:
Abstract
303P - Segmental mandibulectomy without reconstruction
Presenter: Yohei Morishita
Session: Poster display session
Resources:
Abstract